Immuno-Oncology | Specialty

Reckamp Recounts Recent Lung Cancer Advances

January 2nd 2018

Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).

Various Immunotherapy Combinations Continue to Be Explored in NSCLC

December 28th 2017

Daniel E. Haggstrom, MD, discusses the developing area of immunotherapy combinations for patients with non-small cell lung cancer.

The Future of Treatment for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: The Changing Landscape of Treatment

December 28th 2017

Enzalutamide in the Context of Nonmetastatic CRPC

December 28th 2017

Darolutamide's Role in Treating Nonmetastatic CRPC

December 28th 2017

MFS: A New Endpoint for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: Considerations for Apalutamide

December 28th 2017

Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC

December 28th 2017

The Value of AR-Targeted Therapy in CRPC

December 28th 2017

Approaching the Treatment of Nonmetastatic CRPC

December 28th 2017

Understanding Nonmetastatic CRPC: An Overview

December 28th 2017

Treating Advanced Bladder Cancer in the Future

December 28th 2017

Practical Considerations With Checkpoint Inhibitors in Bladder Cancer

December 28th 2017

Immunotherapy in Second-Line Advanced Bladder Cancer

December 28th 2017

Monitoring for Treatment Response in Advanced Bladder Cancer

December 28th 2017

Frontline Immunotherapy in Advanced Bladder Cancer

December 28th 2017

First-Line Chemotherapy in Advanced Bladder Cancer

December 28th 2017

Advanced Bladder Cancer: Predicting Clinical Response

December 28th 2017

Impact of Immunotherapy in Advanced Bladder Cancer

December 28th 2017